Carolyn SP Lam

Jun 12, 2024 | medrxiv.org | Mohammad Ali |Carolyn SP Lam |Anna Stromberg |Anna Strömberg |Simon PP Hand

Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from NovoNordisk and Roche Diagnostics; has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics,...

Oct 18, 2023 | cfrjournal.com | Harriette Van Spall |Giuseppe Rosano |Scott Solomon |Carolyn SP Lam

ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

Jun 21, 2023 | cfrjournal.com | Carolyn SP Lam |John McMurray |Harriette Van Spall |Scott Solomon

"Hello, my name is Martin Cowie, I’m a professor of cardiology. I’m clinical vice president of late stage CVRM, R&D at AstraZeneca. What was the reasoning behind this trial? There’s a huge unmet need in terms of patient symptoms and mortality for those that have a particular form of heart failure called HFpEF with ejection fractions above 40%.And until we had the evidence from SGLT2inhibitors, there was no therapy that had been shown to improve the outcome for those patients. So, a huge unmet need.